Corbus Pharmaceuticals Holdings

Founded in Norwood, Massachusetts, Corbus Pharmaceuticals Holdings is a clinical-stage pharmaceutical company dedicated to developing and commercializing novel therapeutic drugs for inflammatory and fibrotic diseases. Their core mission is to improve the quality of life for patients suffering from these conditions through innovative medical solutions. The company's primary product focus is on lenabasum, a candidate drug designed to treat a range of inflammatory and fibrotic diseases. Corbus Pharmaceuticals operates globally, with services extending to Europe, Israel, and Australia.

Corbus Pharmaceuticals has garnered attention from notable investors and industry experts, contributing to its growing reputation in the biotech sector. The company has achieved significant milestones in its clinical trials, advancing lenabasum through various phases of development. Their work has had a substantial impact on the field of inflammatory and fibrotic disease treatment, offering hope to patients worldwide. Through its commitment to innovation and patient care, Corbus Pharmaceuticals continues to make strides in the pharmaceutical industry.